Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Active not recruiting 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 370Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 142Colorectal Neoplasms 139Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 123Lymphoma 115Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 89Head and Neck Neoplasms 89Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 62Hematologic Neoplasms 59Sarcoma 55Glioma 53

Interventions

Rituximab 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Infectious Mononucleosis × Clear all
NCT04138875 2022-06-23

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Yale University

Phase 2 Withdrawn
Other hematologic neoplasm

Infectious Mononucleosis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡